These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38666024)

  • 1. Ligand-based virtual-screening identified a novel CFTR ligand which improves the defective cell surface expression of misfolded ABC transporters.
    Taniguchi S; Berenger F; Doi Y; Mimura A; Yamanishi Y; Okiyoneda T
    Front Pharmacol; 2024; 15():1370676. PubMed ID: 38666024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced CFTR modulator efficacy in ΔF508 CFTR mouse organoids by ablation of RFFL ubiquitin ligase.
    Hinata D; Fukuda R; Ishiguro H; Kamada Y; Okiyoneda T
    Biochem Biophys Res Commun; 2024 Jul; 733():150433. PubMed ID: 39047427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two
    Graeber SY; Vitzthum C; Pallenberg ST; Naehrlich L; Stahl M; Rohrbach A; Drescher M; Minso R; Ringshausen FC; Rueckes-Nilges C; Klajda J; Berges J; Yu Y; Scheuermann H; Hirtz S; Sommerburg O; Dittrich AM; Tümmler B; Mall MA
    Am J Respir Crit Care Med; 2022 Mar; 205(5):540-549. PubMed ID: 34936849
    [No Abstract]   [Full Text] [Related]  

  • 4. Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.
    Reasoner SA; Bernard R; Waalkes A; Penewit K; Lewis J; Sokolow AG; Brown RF; Edwards KM; Salipante SJ; Hadjifrangiskou M; Nicholson MR
    mBio; 2024 Feb; 15(2):e0193523. PubMed ID: 38275294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of elexacaftor/tezacaftor/ivacaftor on bacterial cultures from people with cystic fibrosis.
    Beck MR; Hornick DB; Pena TA; Singh SB; Wright BA
    Pediatr Pulmonol; 2023 May; 58(5):1569-1573. PubMed ID: 36807558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis.
    Marshall LZ; Espinosa R; Starner CI; Gleason PP
    J Manag Care Spec Pharm; 2023 Jun; 29(6):599-606. PubMed ID: 37276039
    [No Abstract]   [Full Text] [Related]  

  • 7. A novel natural product compound enhances cAMP-regulated chloride conductance of cells expressing CFTR[delta]F508.
    deCarvalho AC; Ndi CP; Tsopmo A; Tane P; Ayafor J; Connolly JD; Teem JL
    Mol Med; 2002 Feb; 8(2):75-87. PubMed ID: 12080183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S945L-CFTR molecular dynamics, functional characterization and tezacaftor/ivacaftor efficacy
    Allan KM; Astore MA; Fawcett LK; Wong SL; Chen PC; Griffith R; Jaffe A; Kuyucak S; Waters SA
    Front Pediatr; 2022; 10():1062766. PubMed ID: 36467478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribosomal Stalk Protein Silencing Partially Corrects the ΔF508-CFTR Functional Expression Defect.
    Veit G; Oliver K; Apaja PM; Perdomo D; Bidaud-Meynard A; Lin ST; Guo J; Icyuz M; Sorscher EJ; Hartman JL; Lukacs GL
    PLoS Biol; 2016 May; 14(5):e1002462. PubMed ID: 27168400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SERCA pump inhibitors do not correct biosynthetic arrest of deltaF508 CFTR in cystic fibrosis.
    Grubb BR; Gabriel SE; Mengos A; Gentzsch M; Randell SH; Van Heeckeren AM; Knowles MR; Drumm ML; Riordan JR; Boucher RC
    Am J Respir Cell Mol Biol; 2006 Mar; 34(3):355-63. PubMed ID: 16284361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Healthcare Resource Utilization and Associated Costs Among People With Cystic Fibrosis in the US: A Retrospective Claims Analysis.
    Schechter MS; Sabater-Anaya N; Oster G; Weycker D; Wu H; Arteaga-Solis E; Bagal S; McGarry LJ; Van Brunt K; Geiger JM
    Pulm Ther; 2023 Dec; 9(4):479-498. PubMed ID: 37874528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two
    Graeber SY; Renz DM; Stahl M; Pallenberg ST; Sommerburg O; Naehrlich L; Berges J; Dohna M; Ringshausen FC; Doellinger F; Vitzthum C; Röhmel J; Allomba C; Hämmerling S; Barth S; Rückes-Nilges C; Wielpütz MO; Hansen G; Vogel-Claussen J; Tümmler B; Mall MA; Dittrich AM
    Am J Respir Crit Care Med; 2022 Aug; 206(3):311-320. PubMed ID: 35536314
    [No Abstract]   [Full Text] [Related]  

  • 13. Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor-Ivacaftor.
    Tümmler B
    Front Pharmacol; 2023; 14():1158207. PubMed ID: 37025483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The short apical membrane half-life of rescued {Delta}F508-cystic fibrosis transmembrane conductance regulator (CFTR) results from accelerated endocytosis of {Delta}F508-CFTR in polarized human airway epithelial cells.
    Swiatecka-Urban A; Brown A; Moreau-Marquis S; Renuka J; Coutermarsh B; Barnaby R; Karlson KH; Flotte TR; Fukuda M; Langford GM; Stanton BA
    J Biol Chem; 2005 Nov; 280(44):36762-72. PubMed ID: 16131493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis.
    Bihler H; Sivachenko A; Millen L; Bhatt P; Patel AT; Chin J; Bailey V; Musisi I; LaPan A; Allaire NE; Conte J; Simon NR; Magaret AS; Raraigh KS; Cutting GR; Skach WR; Bridges RJ; Thomas PJ; Mense M
    J Cyst Fibros; 2024 Jul; 23(4):664-675. PubMed ID: 38388235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy.
    Stanke F; Pallenberg ST; Tamm S; Hedtfeld S; Eichhorn EM; Minso R; Hansen G; Welte T; Sauer-Heilborn A; Ringshausen FC; Junge S; Tümmler B; Dittrich AM
    Front Pharmacol; 2023; 14():1114584. PubMed ID: 36778025
    [No Abstract]   [Full Text] [Related]  

  • 17. Receptor-mediated activation of CFTR via prostaglandin signaling pathways in the airway.
    Shaughnessy CA; Yadav S; Bratcher PE; Zeitlin PL
    Am J Physiol Lung Cell Mol Physiol; 2022 Mar; 322(3):L305-L314. PubMed ID: 35020527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of protein kinase CK2 closes the CFTR Cl channel, but has no effect on the cystic fibrosis mutant deltaF508-CFTR.
    Treharne KJ; Xu Z; Chen JH; Best OG; Cassidy DM; Gruenert DC; Hegyi P; Gray MA; Sheppard DN; Kunzelmann K; Mehta A
    Cell Physiol Biochem; 2009; 24(5-6):347-60. PubMed ID: 19910675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for
    Mall MA; Brugha R; Gartner S; Legg J; Moeller A; Mondejar-Lopez P; Prais D; Pressler T; Ratjen F; Reix P; Robinson PD; Selvadurai H; Stehling F; Ahluwalia N; Arteaga-Solis E; Bruinsma BG; Jennings M; Moskowitz SM; Noel S; Tian S; Weinstock TG; Wu P; Wainwright CE; Davies JC
    Am J Respir Crit Care Med; 2022 Dec; 206(11):1361-1369. PubMed ID: 35816621
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacological Correctors of Mutant CFTR Mistrafficking.
    Pedemonte N; Galietta LJ
    Front Pharmacol; 2012; 3():175. PubMed ID: 23060795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.